XOMA 052 Prevents Adverse Cardiac Remodeling in Animal Model of Heart Attack (GlobeNewswire via Yahoo! Finance)
March 14th, 2010
BERKELEY, Calif. — XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta , significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction .
Original post by macular degeneration – Google News
(click on the author/publication link above to see full post)